HEPCLUDEX

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Romania, Spain.

Active ingredients

The drug HEPCLUDEX contains one active pharmaceutical ingredient (API):

1	Bulevirtide acetate UNII WKM56H3TLB - BULEVIRTIDE
	Bulevirtide blocks the entry of HBV and HDV into hepatocytes by binding to and inactivating NTCP, a bile salt liver transporter serving as essential HBV/HDV entry receptor.
	Read more about Bulevirtide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
HEPCLUDEX Powder for solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AX28		J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AX Other antivirals
Discover more medicines within J05AX28

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1824443
ES	Centro de información online de medicamentos de la AEMPS	1201446001
FR	Base de données publique des médicaments	65804084
IT	Agenzia del Farmaco	048960013
LT	Valstybinė vaistų kontrolės tarnyba	1090963
PL	Rejestru Produktów Leczniczych	100439164
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68364001